Latest News

Pazopanib can induce liver toxicity in patients with metastatic renal cell carcinoma (mRCC). We assessed the effect of a TA repeat polymorphism in the UGT1A1 (uridine diphosphate glucuronosyltransferase 1A1) gene encoding uridine diphosphate glucuronosyltransferase 1A1 on liver toxicity, dose reductions, and patient outcomes. Patients with mRCC treated with first-line pazopanib developing liver toxicity underwent genotyping […]

Effective biomarkers and models are needed to improve the prognostic prospects of clear cell renal cell carcinoma (ccRCC). The purpose of this work was to identify DNA methylation biomarkers and to evaluate the utility of DNA methylation analysis for ccRCC prognosis. An overview of genome-wide methylation of ccRCC tissues derived from The Cancer Genome Atlas […]

Renal cell carcinoma is a common malignancy of the genitourinary system and is the eight most common cancer type in the United States. The overall incidence of renal cell carcinoma appears to be increasing but death rates have been declining. Patients with poor risk, advanced disease have a two-year survival rate of approximately 7%. Prior […]

To evaluate the effect of a prospective opioid reduction intervention after radical prostatectomy (based on a surgery-specific guideline and education) on post-discharge opioid prescribing, use, disposal, and need for additional opioid mediation. A prospective, non-randomized, pre-post interventional trial of patients undergoing radical prostatectomy for prostate cancer (August 2017-November 2018) was conducted as part of ORIOLES. […]

We update the prior AUA SOP for MRI of the prostate and summarize the available data about the technique and clinical use of MRI in the diagnosis and management of prostate cancer. This updated SOP provides practical recommendations for MRI use in the screening, diagnosis, staging, treatment, and surveillance of prostate cancer. A panel of […]

Within five to ten years after radical prostatectomy (RP), approximately 15-34% of prostate cancer (PCa) patients experience biochemical recurrence (BCR), which is defined as recurrence of serum levels of prostate-specific antigen >0. 2 µg/L, indicating probable cancer recurrence. Models using clinicopathological variables for predicting this risk for patients lack accuracy. There is hope that new […]

To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment with 177 Lu-PSMA-617, a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), in men with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel treatment. The TheraP trial (ANZUP 1603) is an open-label, randomized, stratified, […]

Cross resistance between androgen-receptor targeting therapies (ARTs) (abiraterone acetate plus prednisone [ABI+P] or enzalutamide [ENZ]) for treatment of metastatic castration-resistant prostate cancer (mCRPC) may affect responses to second ART (ART2). To establish treatment duration and prostate-specific antigen (PSA) response of ART2 in real-world mCRPC patients treated with or without other life-prolonging drugs (LPDs; ie, docetaxel, […]

Studies have shown a high risk of tumor development within a bladder diverticulum (BD). We were interested in the relationship between BD and the development of bladder cancer. Herein, we attempted to investigate whether there exists an association between documented BD and subsequent risk of bladder cancer. We identified 10,662 hospitalized urology patients, including 2,134 […]

Urothelial carcinoma of the bladder is a heterogeneous disease for which reliable prognostic molecular biomarkers have not been established. To investigate the prognostic value of tumor-associated trypsin inhibitor (TATI) expression combined with p53 expression in bladder cancer patients who have undergone radical cystectomy. Tissue microarrays from 110 patients were analyzed immunohistochemically for TATI and p53 […]